SIGA Technologies, Inc. - 10-Q Summary (Quarter Ended September 30, 2006)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2006, for SIGA Technologies, Inc., a bio-defense company focused on developing products against biological warfare agents (e.g., Smallpox, Arenaviruses) and novel anti-infectives. The company has no commercial products and relies on government grants, contracts, and equity financing to fund research and development (R&D).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Revenues | $2,035,668 | $4,888,987 | $6,232,625 |
| Operating Expenses | $2,995,168 | $9,741,393 | $8,244,515 |
| Net Income (Loss) | $(656,798) | $(5,647,409) | $(2,014,111) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.21) | $(0.08) |
| Cash and Cash Equivalents (End of Period) | $2,649,684 (as of Sep 30, 2006) | ||
| Notes Payable (Current) | $3,107,520 (as of Sep 30, 2006) | ||
| Net Cash Used in Operating Activities | $(2,873,276) (Nine Months 2006) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues for the nine months ended September 30, 2006, decreased by approximately 22% ($1.3 million) compared to the prior year. This was primarily due to a $3.4 million decrease in NIH SBIR grant revenue, partially offset by $2.1 million in revenue from a new USAF contract.
- Increased Expenses: Selling, general, and administrative (SG&A) expenses increased by 56% ($1.1 million) year-over-year, driven by $752,000 in legal and accounting fees related to a terminated merger with PharmAthene, Inc. (PHTN), and a $275,000 non-cash charge for share-based compensation under new accounting standards (SFAS 123(R)).
- Non-Cash Volatility: The company recorded a $721,062 loss for the nine months ended September 30, 2006, due to an increase in the fair market value of common stock rights and warrants classified as liabilities. Conversely, a $350,790 gain was recorded for the quarter.
- Debt Repayment: While notes payable of $3.1 million were outstanding at quarter-end, the company repaid $3.1 million in principal and interest to PHTN on October 23, 2006, shortly after the reporting period.
Guidance, Outlook, and Risks
- New Funding: In late 2006, the company secured significant new funding, including a $16.5 million NIH contract and a $4.8 million SBIR grant for its lead smallpox candidate (SIGA-246), and a $6.0 million grant for Lassa fever antiviral development.
- Capital Raising: In October 2006, the company raised $8.4 million in net proceeds from a securities purchase agreement and an additional $3.0 million from warrant exercises.
- Liquidity: Management believes existing cash and anticipated cash flows from new grants and contracts will support operations for at least the next twelve months.
- Risks: The company faces high risks regarding the completion of its drug development programs, potential inability to secure future financing, and the uncertainty of regulatory approvals. The termination of the PHTN merger requires exclusive negotiation for a license agreement, with no assurance of terms.
- Legal: A lawsuit filed by Four Star Group regarding contract disputes was settled in principle for $35,000 cash and the filing of a registration statement for previously granted warrants.
Investor Verification Checklist
- Grant Recognition: Verify the timing of revenue recognition for the new $27.3 million in NIH contracts/grants awarded in late 2006 to ensure they are booked as services are performed.
- Debt Status: Confirm the full repayment of the $3.1 million PHTN notes payable occurred in October 2006 as stated in the notes.
- Merger Termination: Monitor the status of the exclusive license negotiations with PHTN following the termination of the merger agreement.
- Cash Burn Rate: Assess the sustainability of the current cash position ($2.6 million) against the increased R&D spend for clinical trials of SIGA-246.
- Share-Based Compensation: Review the impact of SFAS 123(R) adoption on future non-cash expenses and diluted share count.